This story is originally published on Biofarma diving. To receive daily news and insights, subscribe to our free daily Bulletin about the diving of Biopharma.
Jeb Keiper, a longtime head of Nimbus Therapeutics, goes to a planned transition that will promote the top executive director of the Biotechnology Startup executive director.
Nimbus said on Friday that Abbas Kazimi, his current Main Business Director, was Appointed executive director immediately in effect. He will replace Keipera, former GSK executive director, who joined Nimbus 11 years ago and has been running the company since 2018.
In his statement, Nimbus said that Kazimi’s appointment was part of the succession plan to create a “next leadership chapter” in the company. Kazimi earned unanimous support for the Committee and was a “critical leader in the last decade of success” in Nimbus, said the Chairman of the Committee and partner atlas Venture Bruce Booth.
“This is the perfect time to transition; The company is on solid ground with an excellent pipeline and a real team that will deliver the next wave of breakthrough medicines for patients, “Keiper UA wrote LinkedIn postadding that he will remain a “dedicated investor” to the company.
Since its formation in 2009, Nimbus has turned into one of the more successful companies in the private state of Biotech, using two lucrative contracts to generate investors’ refund during public markets.
The company was launched As a financial experiment during a great recessionGiven the approach of computer tools of experts to detect drugs of schroderoder and structured as a limited liability company. The branches owned separate programs.
Nimbus took advantage of this approach to the “central part” to improve drug appearances, increased their value, and then sold them on the premium. In 2016, Gilead gained nimbus medicine liver disease for $ 400 million in advance. Three years ago, Takeda paid $ 4 billion in cash For autoimmune diseases See as a future blockbuster.
These contracts, as well as a handful of funding circles, allowed the nimbus to build a considerable bank account over time when the drugs of drugs were difficult to go public.
“We want to build a great organization for research and development not only 13 or 14 years old, for 30 years,” Keiper said in an interview with 2022.
Kazimi will now take over that task. The company has one A prospectus of cancer drugs This recently completed clinical tests at an early stage, and the second this year was referred to people tests. Two others The following are, such as a study of metabolic diseases through a Partnership with Eli Lilly.
